🔗 Share this article

While the US undertakes historic changes to its vaccine guidelines, one figure appears in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by questioning COVID-19 vaccines throughout the pandemic and has zeroed in on potential fatalities following Covid immunization in her brief time at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Health officials had intended to unveil major changes to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would put the US at odds with a large portion of the world with insufficient data for public health gain. This reveal has been delayed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to head the division this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.

The new acting director has repeatedly called for discontinuing certain pediatric shot schedules in the US to become more similar to Denmark, a nation with comprehensive healthcare and a population about the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no obvious track record in medication creation, approval processes or management, which has been standard for former heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since spring.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in managing a large organization. She is not an expert in pharmaceutical oversight.”

Former heads of the center would “grasp regulatory frameworks and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

This division has an enormous workload at the agency, Woodcock emphasized.

“Many people just zeroes in on the new drug program, but the generic program authorizes thousands of generic medications. There is also a biologic copycat branch, OTC medication office and more, and every single one have to be managed,” Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the role, which oversees in excess of 5,000 staff members. “It is a enormous leadership role, if you do it right,” the former official concluded.

Official Statement and Disputed Programs

In response to concerns about Høeg’s credentials and whether this selection indicates increased cooperation among regulatory chiefs on vaccines, a representative stated that the “concerns are based on inaccurate assumptions”.

“Her resume is consistent with the functions of her role,” the representative stated, noting the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched expedited review system, a disputed one-day drug-approval program that reportedly troubled her predecessors. “How are these drugs being chosen for this fast-track system? Who is making the choices?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he said, “the agency appears to be shifting towards less stringent regulations of most medications, with the exception of shots.”

Public Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if problematic, track record, Howard have noted. She authored a study using non-validated public submissions to estimate the incidence of heart inflammation following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are more dangerous than they are.

Among her “desired changes” for the new government encompassed revising guidelines for recently developed shots and discontinuing “non-essential” vaccines, she said following the vote on a online show. At the FDA, Høeg has allegedly floated the idea of barring adolescent males from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who commences with her conclusions and works backwards to fit the science in a extremely misleading, fraudulent way,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|